as of 12-12-2025 2:05pm EST
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Upcoming Earnings Alert:
Get ready for potential market movements as Aptorum Group Limited (APM) prepares to release earnings report on 18 Dec 2025.
| Founded: | 2010 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 10.7M | IPO Year: | 2018 |
| Target Price: | N/A | AVG Volume (30 days): | 104.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.67 - $7.49 | Next Earning Date: | 12-18-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how APM stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "APM Aptorum Group Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.